Compositions and methods for treatment
AssigneeSarcode Bioscience Inc.
InventorsThomas Gadek, John Burnier
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Claims20
A method of treating dry eye disease in a subject in need thereof comprising administering to the subject an effective amount of a lymphocyte function associated antigen-1 (LFA-1) antagonist or a pharmaceutically acceptable salt or ester thereof, wherein the LFA-1 antagonist is
A method of treating dry eye disorder in a subject in need thereof comprising administering to an eye of the subject an effective amount of a pharmaceutical composition comprising a LFA-1 antagonist or a pharmaceutically acceptable salt or ester thereof, wherein the LFA-1 antagonist is
- and whereby the administering is effective in promoting tear secretion or mucin production in said eyes in said subject.
A method of treating dry eye disease in a subject comprising performing a dry eye diagnostic test on the subject;
- determining whether the subject suffers from a dry eye disease based on the results of the diagnostic step;
- and upon diagnosis of the dry eye disease, administering to the subject an effective amount of a LFA-1 antagonist or a pharmaceutically acceptable salt or ester thereof, wherein the LFA-1 antagonist is
A method of treating dry eye disorder in a subject in need thereof comprising administering to an eye of the subject a therapeutically effective amount of a pharmaceutical composition comprising an LFA-1 antagonist and/or its pharmaceutically acceptable salts or ester, wherein said LFA-1 antagonist is
- wherein the administering comprising administering the LFA-1 antagonist in liquid drops topically to a surface of the subject's eyes.
Dependencies are inferred from the claim text.